98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/psyg.70031 | DOI Listing |
Paediatr Drugs
September 2025
Department of Women's and Children's Health, Pediatric Intensive Care Unit, University Hospital of Padua, Padua, Italy.
Background And Objectives: Pediatric delirium (PD) is a common but underdiagnosed condition in pediatric intensive care units (PICUs), affecting 17-66% of patients. It is associated with prolonged ventilation and hospitalization, increased healthcare costs, and mortality. While nonpharmacological approaches are considered first-line treatments, pharmacological interventions are used in refractory cases despite limited pediatric-specific evidence.
View Article and Find Full Text PDFAcute Crit Care
August 2025
National Brain Center, Iran University of Medical Sciences, Tehran, Iran.
Background: Delirium is an acute condition marked by disturbances in cognition, awareness, and attention, commonly observed in hospitalized patients due to factors such as illness severity and medication. It is particularly prevalent in intensive care unit settings, affecting up to 80% of ventilated patients. This study investigates whether coronavirus disease 2019 (COVID-19) delirium aligns with expectations of non-COVID-19 delirium incidence in other hospitalized patients and identifies unique or common factors contributing to delirium in these groups.
View Article and Find Full Text PDFKorean J Anesthesiol
September 2025
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background: Delirium is a common complication among critically ill patients. This study analyzed trends in dexmedetomidine use and its association with delirium incidence, severity, and outcomes in a surgical intensive care unit (ICU).
Methods: A retrospective cohort study was performed in the surgical ICU of a tertiary academic center in South Korea, including 6,140 adult patients admitted from 2017 to 2023.
Brain Sci
August 2025
Department and Clinic of Adult Psychiatry, Faculty of Medical Sciences, Medical University of Silesia, Ziolowa 45, 40-635 Katowice, Poland.
Background and aim of this review: The ongoing opioid epidemic underscores the urgent need for innovative pharmacological and behavioral interventions to mitigate the impact of opioid use disorder (OUD). This review aims to explore theoretical overlaps between the neurobiological mechanisms underlying OUD development and the pharmacodynamic profile of methylphenidate (MPH). Particular attention is given to the potential shared molecular targets, safety considerations, and therapeutic implications of MPH use in this clinical context.
View Article and Find Full Text PDF